Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

ose in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended October 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Jennifer Anderson

(800) 987-8256 (212) 918-4642


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... Texas , Sept. 11, 2014 XBiotech ... high throughput filling machine that the Company says will ... The fully integrated system is designed to fill, stopper ... the manufacturing process. Additionally, the unit is said to ... scanning system to provide a high level of quality ...
(Date:9/11/2014)... 11, 2014 The Registration Committee ... is now open for Pittcon 2015, the world’s ... The event will be held March 8-12, 2015, ... Louisiana. , The discounted registration fee of ... after 2/20/2015). This affordable price includes unlimited week-long ...
(Date:9/11/2014)... Francisco, California (PRWEB) September 11, 2014 ... of software and IT systems that support clinical ... Annotation™ (GVA™) Service that now supports the interpretation ... resulting in a single, user-friendly report that contains ... been used toward cancer treatment planning and support ...
(Date:9/11/2014)... 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... that it intends to conduct a Private Placement ... funding its preclinical development activities and financial commitments ... The Company is proposing to complete a ... shares at a price of US$0.10 per Share, ...
Breaking Biology Technology:Conferee Registration Opens for Pittcon 2015; Housing & Travel Open for Reservations 2CollabRx Launches Expansion of Its Genetic Variation Annotation Service to Support Copy Number Variation (CNV) Data 2CollabRx Launches Expansion of Its Genetic Variation Annotation Service to Support Copy Number Variation (CNV) Data 3Portage Announces Proposed Private Placement 2Portage Announces Proposed Private Placement 3Portage Announces Proposed Private Placement 4
... ... Sciences Division , ... Beijing, China (PRWEB) December 9, 2009 -- China-based CSOFT International Ltd., a leading provider ... for the global market, announced today the hiring of Tammy Werner as Director of ...
... release is available in Spanish . , ... and characterized for the first time different antioxidant compounds from ... herb called Teucrium polium. They have used two new techniques, ... them to identify and quantify a great part of the ...
... , CLEVELAND, Dec. 8 ... the market with a Smart Green(TM) focus. ... packaging, Nutek,s products continue to provide safe alternatives ... (Photo: http://www.newscom.com/cgi-bin/prnh/20091208/CL22934 ) , (Logo: ...
Cached Biology Technology:CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 2CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 3New antioxidant compounds have been identified in foods such as olive oil, honey and nuts 2Nutek, LLC Introduces New Soy-Based, Biodegradable Lubricating and Cleaning Wipes 2
(Date:9/12/2014)... data storage and processing from the user,s computer on ... storage space and computing power that they can then ... to connect to a single desktop or other computer ... concerns about the increased energy demands of sustaining distributed ... an individual user,s laptop might be shut down when ...
(Date:9/12/2014)... of dendritic cells in human skin have assorted functions ... report researchers in the journal EMBO Molecular Medicine ... the composition of dendritic cells in psoriatic skin lesions ... the disease. , "We urgently need new ways ... to patients and reduce the incidence of known side ...
(Date:9/11/2014)... had a Wisconsin zip code if the originally proposed ... a straight line from the southernmost tip of Lake ... River confluence. University of Illinois soil scientist Ken Olson ... changed, the state of Illinois would have a much ... of the Illinois Territory ceded to Wisconsin when it ...
Breaking Biology News(10 mins):Cutting the cloud computing carbon cost 2Dendritic cells affect onset and progress of psoriasis 2Original northern border of Illinois was south of Chicago and Lake Michigan 2Original northern border of Illinois was south of Chicago and Lake Michigan 3
... and measures, Johns Hopkins researchers have shown that ... mystical/spiritual experiences descriptively identical to spontaneous ones people ... experiences apparently prompt positive changes in behavior and ... , The agent, a plant alkaloid called psilocybin, ...
... Researchers at Cold Spring Harbor Laboratory on Long Island have ... brain is the chief target of the widely prescribed antidepressant ... specific treatments for depression, with fewer side effects, to be ... studies of the factors that control how, when, and where ...
... first time that embryonic stem (ES) cells cultured in ... produce viable offspring. The research, published in the July ... future studies, including investigation of mechanisms involved in sperm ... , Previous studies have shown that ES cells grown ...
Cached Biology News:Hopkins scientists show hallucinogen in mushrooms creates universal 'mystical' experience 2Hopkins scientists show hallucinogen in mushrooms creates universal 'mystical' experience 3Hopkins scientists show hallucinogen in mushrooms creates universal 'mystical' experience 4Prozac's target revealed 2Sperm created in the laboratory from embryonic stem cells produce viable progeny 2
...
... Molecular Probes is pleased to ... for the ultrasensitive detection of primary ... at Indiana University, the ATTO-TAG reagents ... o-phthaldialdehyde (OPA), naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, ...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
... low freezers , Ultima II ... material storage, Ultima II represents the finest, ... general purpose and blood bank configurations, each ... microprocessor control system with built-in voltage boost ...
Biology Products: